選單 研討會快訊 最新醫療快訊 藥物安全警訊 學會行事曆 Advances in TRK Fusion-Positive Cancers Education AlertNavigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy0.50 CME / ABIM MOC Are you regularly testing for TRK fusions in cancers with high fusion frequency? 2026-02-07 查看更多 Many Cancers Are Preventable, Study Shows Read More Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC Read More Videos Watch Now Watch Now Trending Read More Read More 2026-02-07 查看更多 How Can Emerging ADC Strategies Help in Early Breast Cancer? 2026-02-07 查看更多 A Radiation Oncology Retrospective 2026-02-06 查看更多 Patient Insights: What Men Really Want from PCa Care 2026-02-06 查看更多 FDA Accepts Application for Camrelizumab Combo FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma Videos Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System Trending 2026-02-05 查看更多 Six-Year Outcomes in CLL and SLL: Insights from the SEQUOIA and ALPINE Trials Chronic Lymphocytic Leukemia/Small-Cell Lymphoma: 6-Year Follow-Up on SEQUOIA and ALPINE LTE1 This program explores evolving strategies in the management of chronic lymphocytic leukemia (CLL), with insights from Drs. Ian Flinn and Danielle Brander. The discussion focuses on the integration of BTK inhibitors and BCL2-targeted therapy, particularly zanubrutinib and venetoclax, highlighting their efficacy, safety, and practical application. Experts emphasize individualized treatment, balancing disease characteristics, comorbidities, and patient preferences, while considering therapy duration and the role of minimal residual disease (MRD)-guided approaches. Featured Video Six-Year Outcomes in CLL and SLL: Insights from the SEQUOIA and ALPINE Trials In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era. 2026-02-05 查看更多 FDA Accepts Ivonescimab BLA in NSCLC FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC FDA OKs Larger Nelarabine Vial in T-Cell Leukemia and Lymphoma Populations New Career Center Video: Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now. Videos Trending Innovation, Elevation, and Empowerment Through Integrative Care in Oncology 2026-02-03 查看更多 89101112